Literature DB >> 25505275

Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance.

Teresa Jurado-Camino1, Raúl Córdoba2, Laura Esteban-Burgos1, Enrique Hernández-Jiménez1, Victor Toledano1, Jose-Angel Hernandez-Rivas3, Elena Ruiz-Sainz4, Teresa Cobo5, María Siliceo1, Rebeca Perez de Diego6, Cristobal Belda7, Carolina Cubillos-Zapata8, Eduardo López-Collazo9.   

Abstract

Infections are a significant cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). The pathogenesis of infections is multifactorial and includes hypogammaglobulinemia, conventional therapy with alkylating drugs, and recently, purine analogs and mAb-associated T cells. Patients without these risk factors also suffer from infections, although the mechanism remains unknown. In a cohort of 70 patients with CLL, we demonstrated that their monocytes were locked into a refractory state and were unable to mount a classic inflammatory response to pathogens. In addition, they exhibited the primary features of endotoxin tolerance, including low cytokine production, high phagocytic activity, and impaired Ag presentation. The involvement of miR-146a in this phenomenon was suspected. We found miR-146a target genes, such as IRAK1 and TRAF6, were manifestly downregulated. Our study provides a new explanation for infections in patients with CLL and describes a cross-tolerance between endotoxins and tumors.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505275     DOI: 10.4049/jimmunol.1402272

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

2.  The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.

Authors:  M Qorraj; H Bruns; M Böttcher; L Weigand; D Saul; A Mackensen; R Jitschin; D Mougiakakos
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

3.  Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia.

Authors:  Carolina Cubillos-Zapata; Jose Avendaño-Ortiz; Raúl Córdoba; Enrique Hernández-Jiménez; Victor Toledano; Rebeca Pérez de Diego; Eduardo López-Collazo
Journal:  Oncoimmunology       Date:  2016-10-20       Impact factor: 8.110

4.  Cytokine Release Ensuing Interaction Between Human Peripheral Blood Mononuclears and Epstein-Barr Virus Transformed B-CLL Cell Line.

Authors:  Hanna Bessler; Chiya Moshe Leibovitch; Meir Djaldetti
Journal:  J Immunother Precis Oncol       Date:  2020-04-28

Review 5.  'Trained immunity': consequences for lymphoid malignancies.

Authors:  Wendy B C Stevens; Mihai G Netea; Arnon P Kater; Walter J F M van der Velden
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

Review 6.  Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Authors:  Silvia Sánchez-Ramón; Fatima Dhalla; Helen Chapel
Journal:  Front Immunol       Date:  2016-08-22       Impact factor: 7.561

7.  A System Dynamics Model to Predict the Human Monocyte Response to Endotoxins.

Authors:  Enrique Álvarez; Víctor Toledano; Fernando Morilla; Enrique Hernández-Jiménez; Carolina Cubillos-Zapata; Aníbal Varela-Serrano; José Casas-Martín; José Avendaño-Ortiz; Luis A Aguirre; Francisco Arnalich; Charbel Maroun-Eid; Alejandro Martín-Quirós; Manuel Quintana Díaz; Eduardo López-Collazo
Journal:  Front Immunol       Date:  2017-08-03       Impact factor: 7.561

Review 8.  Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.

Authors:  Martijn Ha van Attekum; Eric Eldering; Arnon P Kater
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

9.  MiR-146b Mediates Endotoxin Tolerance in Human Phagocytes.

Authors:  Tiziana Ada Renzi; Marcello Rubino; Laura Gornati; Cecilia Garlanda; Massimo Locati; Graziella Curtale
Journal:  Mediators Inflamm       Date:  2015-09-14       Impact factor: 4.711

10.  Galactomannan Downregulates the Inflammation Responses in Human Macrophages via NFκB2/p100.

Authors:  Víctor Toledano; Enrique Hernández-Jiménez; Carolina Cubillos-Zapata; Marta Flandez; Enrique Álvarez; Aníbal Varela-Serrano; Ramón Cantero; Gema Valles; Francisco García-Rio; Eduardo López-Collazo
Journal:  Mediators Inflamm       Date:  2015-09-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.